Trial reportClinical and translational science2013
Initiation of aspirin therapy modulates angiogenic protein levels in women with breast cancer receiving tamoxifen therapy.
Trial report in Clinical and translational science, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Antiplatelet Therapy in Breast Cancer Patients Using Hormonal Therapy: Myths, Evidence and Potentialities - Systematic Review.Arquivos brasileiros de cardiologia · 2018Pooled it
- Study on the mechanism of MDSC-platelets and their role in the breast cancer microenvironment.Frontiers in cell and developmental biology · 2024Review
- Platelets in the tumor microenvironment and their biological effects on cancer hallmarks.Frontiers in oncology · 2023Review
- The Provocative Roles of Platelets in Liver Disease and Cancer.Frontiers in oncology · 2021Review
- Platelet Count is Associated with the Rate of Lymph Node Metastasis in Lung Adenocarcinoma.Cancer management and research · 2020Article
- PRIMMO study protocol: a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer.BMC cancer · 2019Article
- Aspirin inhibits platelets from reprogramming breast tumor cells and promoting metastasis.Blood advances · 2019Article
- Aspirin, a Potential GLUT1 Inhibitor in a Vascular Endothelial Cell Line.Open medicine (Warsaw, Poland) · 2019Article
- The Platelet Lifeline to Cancer: Challenges and Opportunities.Cancer cell · 2018Review
- Human expression patterns: qualitative and quantitative analysis of thrombospondin-1 under physiological and pathological conditions.Journal of cellular and molecular medicine · 2018Review
- Platelet Metabolism and Other Targeted Drugs; Potential Impact on Immunotherapy.Frontiers in oncology · 2018Review
- Baseline thrombospondin-1 concentrations are not associated with mortality in septic patients: a single-center cohort study on the intensive care unit.Intensive care medicine experimental · 2017Article
- Role of Aspirin in Breast Cancer Survival.Current oncology reports · 2017Review
- Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention.Cancer metastasis reviews · 2017Review
- Platelet "first responders" in wound response, cancer, and metastasis.Cancer metastasis reviews · 2017Review
- Activated platelets inhibit hepatocellular carcinoma cell differentiation and promote tumor progression via platelet-tumor cell binding.Oncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aspirin has a range of antineoplastic properties linked to inhibition of cyclooxygenase enzymes in tumor cells, platelet inhibition and to inhibition of angiogenesis. We undertook a prospective study to determine the influence of a 45-day course of aspirin therapy on circulating and intraplatelet levels of selected proangiogenic (vascular endothelial growth factor [VEGF]) and antiangiogenic (thrombospondin-1 [TSP-1]) proteins, and platelet protein release in women diagnosed with breast cancer who were receiving tamoxifen therapy. Initiation of aspirin therapy increases serum and intraplatelet levels of TSP-1 without a corresponding increase in VEGF levels. Following aspirin therapy, VEGF levels decreased (relative to pretreatment levels) while TSP-1 returned to pretreatment levels. Plasma TSP-1 and VEGF levels did not change on aspirin therapy. Aspirin use also decreased thrombin receptor mediated release of TSP-1 and VEGF from platelets. The selective impact on platelet angiogenic protein content and release supports one mechanism by which aspirin can modify the angiogenic balance in women receiving tamoxifen therapy. Aspirin therapy appears to favor an overall antiangiogenic balance in women with breast cancer who are receiving tamoxifen therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.